In Vivo’s ’30 Rising Leaders’ 2023

Each year, In Vivo spotlights the next wave of entrepreneurs and innovators making a difference in the biopharma, medtech and health technology sectors. The 30 Rising Leaders have been recognised for their achievements, talent, creativity and leadership and this year include four of Optimum’s fantastic clients. 

Firstly, Anthony DeBoer, VP of Business Development at Synaffix, has been recognised for leading Synaffix’s entire deal-making process with pharma and biotech companies. His efforts at Synaffix have resulted in 13 partnerships across the globe, leading to 22 Antibody-Drug Conjugates (ADCs) in development, where 5 programs have commenced clinical development. In 2023 alone, Anthony has led Synaffix’s $2billion deal with Amgen, a $2.2 billion deal expansion with MacroGenics along with deals with Hummingbird and Chong Kun Dang Pharm.  

Sofinnova’s Principal and Program Director for its MedTech Strategy (MD Start), Cécile Dupont, also made the list for 2023. Since she joined Sofinnova in 2019, Cécile’s operational and strategic expertise has been invaluable in leading number of medical device portfolio companies. Cécile is currently CEO of HEPTA Medical, a medtech company developing a minimally invasive non-surgical treatment modality for early lung cancer. 

The next Rising Leader is Miquel Vila-Perelló, PhD, the Co-Founder & CEO of SpliceBio, the biotech company exploiting protein splicing to develop the next-gen of gene therapies. Miquel has made a significant contribution to the discovery and development of novel protein ligation technologies over the past 10 years. Since co-founding SpliceBio, Miquel led the Company’s successful oversubscribed EUR 50M Series A financing in February 2022. 

Last but by no means least is Jesper Kimer, the Co-founder and CEO of digital therapeutics company, HEI Therapeutics. As part of the BioInnovation Institute’s Venture Lab program, HEI is developing the world’s first medical-grade home monitoring solution for patients with hypothyroidism. Jesper’s leadership has also resulted in the Company being selected by the Texas Medical Centre to take part in its accelerator program to gain access and exposure to the US market. 

You can read more about the fantastic Rising Leaders here